Full Year 2023 Investor Presentation
75
Investor presentation
Full year 2023
The cardiovascular trial, SELECT, addresses many comorbidities
that can be improved with weight management
Weight loss (%)
30
Improvements (examples)
20
10
0-5%
0
Improvements per weight loss bracket
5-10%
>15%
10-15%
Hypertension
X
Hyperglycaemia
X
Prevention of T2D
Dislipidaemia
X
Kidney disease
Cardiovascular Disease
MASH
CV mortality
X
MAFLD
GERD
HF
X
SELECT trial endpoints
✓ Primary
X Secondary
O Exploratory
PCOS
OSAS
Knee OA
T2D remission
T2D: Type 2 diabetes; MAFLD: Metabolic dysfunction-associated fatty liver disease; PCOS: Polycystic ovary syndrome; MASH: Metabolic dysfunction-associated steatohepatitis; GERD: Gastroesophageal reflux disease; OSAS: Obstructive sleep apnea syndrome; OA:
Osteoarthritis HF: Heart failure
Sources: Garvey WT et al. Endocr Pract 2016;22(Suppl. 3):1-203; Look AHEAD Research Group. Lancet Diabetes Endocrinol 2016;4:913-21; Lean ME et al. Lancet 2018;391:541-5; Benraoune F and Litwin SE. Curr Opin Cardiol 2011;26:555-61; Sundström J et al.
Circulation 2017;135:1577-85., Morales E and Praga M. Curr Hypertens Rep 2012;14:170-176
Novo NordiskⓇView entire presentation